GlaxoSmithKline Net Debt from 2010 to 2024

GSK Stock

USD 33.96 0.26 0.77%

GlaxoSmithKline PLC Net Debt yearly trend continues to be quite stable with very little volatility. The value of Net Debt is projected to decrease to about 8.3 B. Net Debt is the total debt of GlaxoSmithKline PLC ADR minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1986-06-30

Previous Quarter

-3.2 B

Current Value

-3.2 B

Quarterly Volatility

7.8 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many indicators such as Price To Sales Ratio of 1.84, Dividend Yield of 0.0451 or PTB Ratio of 8.65. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.

Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Latest GlaxoSmithKline PLC's Net Debt Growth Pattern

Below is the plot of the Net Debt of GlaxoSmithKline PLC ADR over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. GlaxoSmithKline PLC's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

GlaxoSmithKline Net Debt Regression Statistics

	Arithmetic Mean	14,522,880,991
	Geometric Mean	10,458,913,307
	Coefficient Of Variation	43.49
	Mean Deviation	4,527,561,874
	Median	14,118,000,000
	Standard Deviation	6,315,887,305
	Sample Variance	39890432.4T
	Range	25.7B
	R-Value	0.49
	Mean Square Error	32555044.1T
	R-Squared	0.24
	Significance	0.06
	Slope	695,008,943
	Total Sum of Squares	558466054.3T

GlaxoSmithKline Net Debt History

	2024	8.3 B
	2023	15.1 B
	2022	17.3 B
	2021	19.9 B
	2020	20.9 B
	2019	25.8 B
	2018	22.2 B

Other Fundumenentals of GlaxoSmithKline PLC ADR

Net Debt To E B I T D A

GlaxoSmithKline PLC Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Treasury Stock	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Cash And Equivalents
Total Assets		0.5	0.9	0.33	-0.02	0.97	0.91	0.7	0.71	0.7	0.11	0.94	0.5	0.95	-0.16	0.23	0.35	0.19	-0.26	0.57	-0.59	0.59	0.4	0.49	0.5	0.2
Total Stockholder Equity	0.5		0.43	-0.44	0.2	0.31	0.48	0.33	0.25	0.33	0.88	0.51	0.38	0.68	-0.23	0.1	0.33	0.13	0.06	0.75	-0.27	0.78	0.7	0.42	0.82	-0.44
Net Debt	0.9	0.43		0.38	-0.01	0.89	0.82	0.65	0.9	0.65	0.07	0.82	0.64	0.84	0.02	0.2	0.42	0.11	-0.05	0.47	-0.49	0.65	0.32	0.58	0.5	0.24
Accounts Payable	0.33	-0.44	0.38		-0.33	0.5	0.3	0.43	0.49	0.43	-0.71	0.3	0.22	0.16	0.18	0.04	0.22	-0.07	-0.19	-0.09	-0.22	-0.11	-0.27	0.15	-0.3	0.26
Short Term Investments	-0.02	0.2	-0.01	-0.33		-0.02	0.17	-0.03	0.0	-0.03	0.24	-0.14	-0.18	0.03	-0.34	0.15	-0.01	0.18	0.17	0.33	-0.16	-0.03	0.36	-0.33	0.44	-0.09
Total Liab	0.97	0.31	0.89	0.5	-0.02		0.91	0.74	0.75	0.74	-0.11	0.88	0.47	0.86	-0.15	0.23	0.31	0.2	-0.27	0.48	-0.63	0.46	0.33	0.42	0.4	0.25
Total Current Assets	0.91	0.48	0.82	0.3	0.17	0.91		0.88	0.65	0.88	0.05	0.72	0.6	0.79	-0.04	-0.04	0.14	0.15	-0.2	0.48	-0.54	0.41	0.41	0.31	0.47	0.13
Capital Stock	0.7	0.33	0.65	0.43	-0.03	0.74	0.88		0.55	1.0	-0.13	0.49	0.74	0.55	0.23	-0.33	-0.01	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Short Term Debt	0.71	0.25	0.9	0.49	0.0	0.75	0.65	0.55		0.55	-0.04	0.65	0.56	0.66	0.12	0.25	0.58	-0.1	0.14	0.34	-0.31	0.55	0.19	0.54	0.37	0.21
Common Stock	0.7	0.33	0.65	0.43	-0.03	0.74	0.88	1.0	0.55		-0.13	0.49	0.74	0.55	0.23	-0.33	-0.01	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Retained Earnings	0.11	0.88	0.07	-0.71	0.24	-0.11	0.05	-0.13	-0.04	-0.13		0.2	0.03	0.36	-0.3	0.18	0.33	0.04	0.2	0.61	0.01	0.66	0.62	0.32	0.71	-0.47
Intangible Assets	0.94	0.51	0.82	0.3	-0.14	0.88	0.72	0.49	0.65	0.49	0.2		0.38	0.96	-0.26	0.4	0.48	0.22	-0.31	0.61	-0.57	0.7	0.35	0.57	0.51	0.14
Long Term Debt	0.5	0.38	0.64	0.22	-0.18	0.47	0.6	0.74	0.56	0.74	0.03	0.38		0.44	0.65	-0.46	-0.03	-0.19	0.1	0.03	-0.06	0.29	-0.08	0.25	0.12	0.13
Good Will	0.95	0.68	0.84	0.16	0.03	0.86	0.79	0.55	0.66	0.55	0.36	0.96	0.44		-0.26	0.36	0.5	0.21	-0.17	0.73	-0.58	0.76	0.52	0.56	0.67	0.03
Property Plant Equipment	-0.16	-0.23	0.02	0.18	-0.34	-0.15	-0.04	0.23	0.12	0.23	-0.3	-0.26	0.65	-0.26		-0.65	-0.26	-0.59	0.35	-0.64	0.54	-0.34	-0.65	-0.17	-0.56	0.39
Current Deferred Revenue	0.23	0.1	0.2	0.04	0.15	0.23	-0.04	-0.33	0.25	-0.33	0.18	0.4	-0.46	0.36	-0.65		0.73	0.16	0.21	0.57	-0.42	0.46	0.45	0.35	0.49	-0.12
Net Receivables	0.35	0.33	0.42	0.22	-0.01	0.31	0.14	-0.01	0.58	-0.01	0.33	0.48	-0.03	0.5	-0.26	0.73		-0.23	0.42	0.6	-0.17	0.59	0.45	0.46	0.48	-0.22
Treasury Stock	0.19	0.13	0.11	-0.07	0.18	0.2	0.15	0.03	-0.1	0.03	0.04	0.22	-0.19	0.21	-0.59	0.16	-0.23		-0.5	0.37	-0.78	0.22	0.34	0.1	0.33	-0.23
Net Tangible Assets	-0.26	0.06	-0.05	-0.19	0.17	-0.27	-0.2	-0.16	0.14	-0.16	0.2	-0.31	0.1	-0.17	0.35	0.21	0.42	-0.5		0.04	0.24	0.01	0.15	-0.04	0.12	-0.13
Long Term Investments	0.57	0.75	0.47	-0.09	0.33	0.48	0.48	0.25	0.34	0.25	0.61	0.61	0.03	0.73	-0.64	0.57	0.6	0.37	0.04		-0.65	0.76	0.88	0.45	0.92	-0.52
Short Long Term Debt	-0.59	-0.27	-0.49	-0.22	-0.16	-0.63	-0.54	-0.4	-0.31	-0.4	0.01	-0.57	-0.06	-0.58	0.54	-0.42	-0.17	-0.78	0.24	-0.65		-0.4	-0.56	-0.25	-0.53	0.24
Long Term Debt Total	0.59	0.78	0.65	-0.11	-0.03	0.46	0.41	0.18	0.55	0.18	0.66	0.7	0.29	0.76	-0.34	0.46	0.59	0.22	0.01	0.76	-0.4		0.6	0.81	0.83	-0.29
Capital Surpluse	0.4	0.7	0.32	-0.27	0.36	0.33	0.41	0.21	0.19	0.21	0.62	0.35	-0.08	0.52	-0.65	0.45	0.45	0.34	0.15	0.88	-0.56	0.6		0.36	0.87	-0.59
Net Invested Capital	0.49	0.42	0.58	0.15	-0.33	0.42	0.31	0.14	0.54	0.14	0.32	0.57	0.25	0.56	-0.17	0.35	0.46	0.1	-0.04	0.45	-0.25	0.81	0.36		0.52	-0.1
Net Working Capital	0.5	0.82	0.5	-0.3	0.44	0.4	0.47	0.21	0.37	0.21	0.71	0.51	0.12	0.67	-0.56	0.49	0.48	0.33	0.12	0.92	-0.53	0.83	0.87	0.52		-0.47
Cash And Equivalents	0.2	-0.44	0.24	0.26	-0.09	0.25	0.13	-0.02	0.21	-0.02	-0.47	0.14	0.13	0.03	0.39	-0.12	-0.22	-0.23	-0.13	-0.52	0.24	-0.29	-0.59	-0.1	-0.47

Click cells to compare fundamentals

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC investors utilize fundamental indicators, such as Net Debt, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	15.1 B	8.3 B
Net Debt To EBITDA	1.65	0.92

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.28)

Dividend Share

0.61

Earnings Share

1.53

Revenue Per Share

15.38

Quarterly Revenue Growth

(0.02)

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlaxoSmithKline Net Debt from 2010 to 2024

Latest GlaxoSmithKline PLC's Net Debt Growth Pattern

GlaxoSmithKline Net Debt Regression Statistics

GlaxoSmithKline Net Debt History

Other Fundumenentals of GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC Net Debt component correlations

About GlaxoSmithKline PLC Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY